Open AccessReply to Aitken et al., “Should Piperacillin-Tazobactam Be Used as Definitive Therapy against Enterobacteriaceae Harboring Inducible AmpC β-Lactamases?”
Author(s) -
Lucy Cheng,
Brian Nelson,
Monica Mehta,
Qiuhu Shi,
Angela GomezSimmonds,
AnneCatrin Uhlemann
Publication year - 2017
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01163-17
Subject(s) - piperacillin/tazobactam , enterobacteriaceae , piperacillin , tazobactam , microbiology and biotechnology , medicine , gram negative bacterial infections , biology , antibiotics , bacteria , antibiotic resistance , escherichia coli , imipenem , genetics , gene , pseudomonas aeruginosa
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom